Description
Ceppra (Levetiracetam) Coated Tablets 1000 mg. №30
Composition
The active ingredient in Ceppra is levetiracetam. Each tablet contains 1000 mg of levetiracetam.
Mechanism of Action
Ceppra exerts its antiepileptic effects by binding to the synaptic vesicle protein 2A (SV2A) in the brain, which modulates neurotransmitter release and helps regulate neuronal excitability.
Pharmacological Properties
Levetiracetam, the active component of Ceppra, is a pyrrolidine derivative that exhibits antiepileptic activity. It does not interfere with classical antiepileptic drugs and has a unique mechanism of action.
Indications for Use
Ceppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents aged 16 years and older with newly diagnosed epilepsy.
Contraindications
- Patients with known hypersensitivity to levetiracetam or any of the other components of the formulation.
- Patients with severe renal impairment as levetiracetam is primarily excreted unchanged by the kidneys.
- Patients with a history of psychotic disorders due to the potential exacerbation of psychiatric symptoms.
Side Effects
The common side effects of Ceppra may include somnolence, asthenia, dizziness, and behavioral abnormalities. Serious side effects such as suicidal behavior and hematological abnormalities have also been reported.
Usage Instructions
Ceppra tablets should be swallowed whole with a glass of water. The recommended dosage for adults and adolescents is 1000 mg twice daily. The tablets can be taken with or without food, and they should not be crushed or chewed.
Benefits Compared to Analogues
Ceppra, with its unique mechanism of action and favorable side effect profile, offers a valuable treatment option for patients with epilepsy. Compared to traditional antiepileptic drugs, Ceppra has a lower potential for drug interactions and a reduced risk of cognitive impairment.
Suitable Patient Groups
Ceppra is suitable for use in various patient populations, including adults and adolescents aged 16 years and older. It has also been found to be well-tolerated in the elderly and can be considered for use in this age group under appropriate medical supervision.
Storage Conditions and Shelf Life
Ceppra tablets should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from light and moisture. The shelf life of Ceppra tablets is typically 24 months from the date of manufacture.
Packaging Description
Ceppra tablets are available in blister packs containing 30 coated tablets of 1000 mg strength. The packaging is designed to ensure the stability and integrity of the tablets throughout their shelf life.
